CION Ameerpet
Immunotherapy · Rectal & Lower GI Cancer
Immunotherapy Before Surgery for MSI-High Rectal Cancer — Who Qualifies
For most people with rectal cancer, immunotherapy before surgery is not an option. It applies only when the tumour is MSI-High, also written dMMR — roughly 5 to 10 in every 100 rectal cancers. In that small group, treatment given before surgery has sometimes cleared the tumour completely, allowing the operation to be deferred and the rectum kept.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- One line in the pathology report decides it — MMR or MSI status, not the stage and not the symptoms, determines whether this approach is even possible for you.
- Roughly 5 to 10 in 100 rectal cancers qualify — Most patients are not candidates. Hearing that plainly, early, prevents months of chasing an option that was never available.
- What is at stake is the rectum itself — For the small eligible group, deferring surgery can mean avoiding a stoma. It is a possibility that has to be earned, not a certainty.
- If your report says MSS, you still have treatment — Chemoradiation and surgery remain the established, evidence-based path for the large majority of rectal cancers.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
Can Surgery Be Avoided for MSI-High Rectal Cancer?
For most rectal cancer patients, no. Immunotherapy before surgery applies only when the tumour is MSI-High, also written dMMR. That is roughly 5 to 10 in every 100 rectal cancers. For the other 90 or so, chemoradiation and surgery remain the evidence-based path, and no immunotherapy schedule changes that.
For the small group who are MSI-High, something genuinely unusual is possible. In carefully selected patients with locally advanced MSI-High rectal cancer, checkpoint inhibitor immunotherapy given before surgery has left no tumour detectable on digital examination, on endoscopy and on pelvic MRI. Where that happens, surgery and pelvic radiation can be deferred rather than performed on schedule. The rectum is preserved.
That matters more than a treatment sequence usually does. Standard treatment for a low rectal cancer often means a stoma, sometimes temporary, sometimes permanent, along with lasting changes to bowel, bladder and sexual function. Being told the operation might be deferred is a completely different conversation from being told it is unavoidable.
It is also why the result has to be explained carefully rather than advertised. The numbers of patients studied are small. Follow-up is still maturing. Deferring surgery is not the same as being finished with cancer, and it commits you to years of close surveillance instead. Any centre presenting this as a routine, settled choice is overstating what is known.
Eligibility is decided by a tumour board reading your actual tissue report and pelvic MRI, not by this page. If you have not been told your MMR or MSI result, that is the first thing to ask for.
Eligibility, precisely
Who Is Eligible for Immunotherapy Before Rectal Cancer Surgery?
Five things have to line up together. Missing any one of them takes the option off the table, however much the others fit.
| Requirement | What it means | How it is established |
|---|---|---|
| dMMR or MSI-High confirmed on tissue | The mismatch repair system is not working, so the tumour carries many abnormal proteins and is visible to immune cells | Immunohistochemistry for MLH1, MSH2, MSH6 and PMS2 on tissue already taken, or PCR or next-generation sequencing for microsatellite instability |
| Rectal, locally advanced, not spread | Disease confined to the rectum and nearby lymph nodes rather than metastatic | Pelvic MRI, colonoscopy and CT of the chest and abdomen, coordinated at partner imaging centres |
| No condition that rules immunotherapy out | Active autoimmune disease needing immune-suppressing treatment, a transplanted organ, or high baseline steroid doses can make it unsafe | Medical history, a full medication review, and baseline blood tests before any decision is made |
| Baseline safety screening completed | Hepatitis B and C status, thyroid, liver, kidney and blood counts recorded before the first cycle | Routine pre-treatment protocol for everyone starting immunotherapy, not a comment on your history |
| Able to attend intensive surveillance | Repeated examination, endoscopy and pelvic MRI at close intervals for years, not months | Discussed and agreed before treatment starts, including the travel, time and cost it involves |
| Agreed at a tumour board with a colorectal surgeon | Deferring an operation is a surgical decision as much as a medical one | Multidisciplinary review, with the surgeon staying involved throughout the surveillance years |
MSS or pMMR rectal cancer is not on this pathway. That is roughly 9 in every 10 patients. Chemoradiation, total neoadjuvant therapy and surgery are the established treatments there. A watch-and-wait discussion does exist in MSS rectal cancer at some centres, but it follows response to chemoradiation and has its own separate criteria. The two should not be read as the same offer.
Did you know?
dMMR is less common in the rectum than in the colon. Across all colorectal cancers taken together, roughly 15 in 100 are MSI-High. In rectal cancer specifically it is closer to 5 to 10 in 100. An eligibility figure lifted from a colon cancer article and applied to a rectal tumour can set expectations far too high, which is one of the commonest reasons families arrive disappointed.
What the evidence actually shows
What Is the Evidence for Not Operating?
It comes from small cohorts, not from large randomised trials. In patients with locally advanced dMMR rectal cancer given checkpoint inhibitor immunotherapy alone before surgery, a high proportion had no detectable tumour afterwards and were able to defer surgery and radiation. NCCN guidance current as of August 2026 lists this as an option.
The finding that drew attention was reported from a single centre in the United States, in the New England Journal of Medicine in 2022. In that first cohort of about a dozen patients, all had a clinical complete response, with no tumour found on examination, endoscopy or MRI, and none proceeded to surgery or radiation at that point. Larger cohorts and longer follow-up have been reported since, and guideline bodies have moved from treating it as a curiosity to listing it as an option.
What is not yet known matters just as much. How durable the benefit is across many years is still being established. Regrowth after an initial complete response is a recognised event in organ-preservation programmes generally, which is precisely why surveillance is intensive rather than reassuring. Whether results achieved at specialist centres, with expert MRI reporting and near-perfect follow-up attendance, translate to ordinary practice has not been settled. Long-term data on late immune-related effects in people treated in their forties and fifties do not yet exist.
So the honest framing is this. For a small, biomarker-defined group, an option now exists that did not exist a few years ago, and it is recognised in guidelines. It is not a settled standard for every dMMR rectal cancer. It is not offered as a certainty. And it is not a reason to leave a pathology report unchased while a decision waits.
No survival figures appear anywhere on this page. Response findings describe what happened to tumours in a studied group. They are not a prediction for you, and any number about your own outlook belongs in a consultation with your report on the table.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Know Your MMR/MSI Status Before the Operation Is Scheduled
A medical oncologist and a colorectal surgeon will review your report together, explain what your MMR/MSI result changes, and set out the realistic options either way. Free, confidential, with no commitment to start treatment.
Step by step
What Does the Non-Operative Pathway Actually Involve?
Deferring surgery is not a lighter version of treatment. It is a different and more demanding follow-up commitment. These are the steps, in order.
1
Confirm dMMR or MSI-High on tissue, not on assumption
The MMR or MSI result is confirmed on the tumour tissue report before anything else is planned. Where the report is old, unclear, or from another laboratory, the slides are re-read rather than taken on trust. One line in that report decides the entire pathway.
2
Stage the tumour properly, with the surgeon already involved
Pelvic MRI, colonoscopy and CT of the chest and abdomen establish that the disease is locally advanced and has not spread. Imaging is coordinated at partner imaging centres rather than performed in-house. A colorectal surgeon reviews the case at tumour board from the start, because the operation being deferred is theirs.
3
Complete baseline safety screening, including hepatitis B and C
Hepatitis B and C screening before immunotherapy is routine protocol for everyone, not a comment on your history. Immune-related side effects are sometimes treated with steroids or other immune-suppressing medicines, and a past hepatitis infection can reactivate under that suppression. Thyroid, liver, kidney and blood-count baselines are taken at the same visit, so later changes can be recognised rather than guessed at.
4
Treatment as day care, over months rather than weeks
Checkpoint inhibitor immunotherapy is administered as day care at CION centres, so an overnight stay is not usually needed. The course runs over several months. Side effects are immune-related rather than chemotherapy-like, and any new symptom is reported early instead of waited out.
5
Assess response three ways, then keep assessing
A clinical complete response means no tumour detectable on digital examination, on endoscopy and on pelvic MRI, judged together. One normal scan is not enough. If a complete response is confirmed, surveillance continues at close intervals for years. If tumour remains or regrows, surgery is brought back, with the same intent it would have had earlier.
Side by side
How Does This Compare With Standard Rectal Cancer Treatment?
The two pathways are chosen by biomarker, not by preference. The table below sets them out on the same rows so the trade-offs are visible.
| Standard pathway (MSS or pMMR) | Immunotherapy-first pathway (dMMR or MSI-High) | |
|---|---|---|
| Who it applies to | Roughly 9 in every 10 rectal cancers | Roughly 5 to 10 in every 100 rectal cancers |
| What is given first | Chemoradiation, often with chemotherapy, as total neoadjuvant therapy | Checkpoint inhibitor immunotherapy alone, over several months |
| Pelvic radiation | Usually part of treatment | May be deferred if the response is complete |
| Surgery | Planned from the outset | Deferred only if no tumour is detectable; performed if tumour remains or regrows |
| Stoma | Common, and sometimes permanent for low tumours | May be avoided altogether in the group that responds completely |
| Follow-up intensity | Standard post-surgical surveillance | Intensive: repeated examination, endoscopy and pelvic MRI for years |
| Strength of evidence | Large randomised trials built up over decades | Small cohorts with maturing follow-up; listed as an option in NCCN guidance as of August 2026 |
| If it does not work | Treatment is adjusted and surgery proceeds | Surgery proceeds, with the same intent it would have had earlier |
Cost also differs, and the direction is not obvious. Immunotherapy given over months is expensive, while surgery and radiation carry their own admission, theatre and recovery costs. Any figure quoted for either is indicative only, as of August 2026, and depends on the regimen, the number of cycles and your scheme cover. ArogyaSri, CGHS and cashless insurance are accepted, and what each covers is set out in a costing discussion before treatment starts, not afterwards.
Said plainly
What This Approach Does Not Promise
The result is striking, which is exactly why the limits belong on the same page rather than in a footnote.
- It does not promise that surgery will be avoided — a complete response has to be demonstrated on examination, endoscopy and MRI before an operation is deferred, and not everyone reaches that point.
- Deferring is not the same as finishing — surveillance continues at close intervals for years. That intensity is the price of keeping the rectum, and it has to be accepted in advance.
- Regrowth is possible and is planned for — if tumour returns during surveillance, surgery is performed then. This is why the colorectal surgeon stays involved rather than stepping away.
- Immunotherapy carries its own risks — immune-related effects can involve the bowel, lungs, liver, thyroid, adrenal glands and heart. Most are manageable when reported early. Some are serious. Avoiding an operation does not remove that.
- No outlook figure is being offered here — this page describes eligibility, evidence and process. Any number about your own prognosis belongs in a consultation with your report in front of the team, not on a web page.
Answers before decisions
One Test Decides This. Find Out Where You Stand.
dMMR or MSS, you deserve to hear it plainly and to know exactly what each answer changes about surgery. A medical oncologist will go through your report and the realistic options with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy Before Rectal Cancer Surgery — Your Questions Answered
Can surgery be avoided for rectal cancer with immunotherapy?
Only for a small group. Immunotherapy before surgery is an option when the rectal tumour is dMMR or MSI-High, which is roughly 5 to 10 in every 100 rectal cancers. In that group, checkpoint inhibitor immunotherapy given before surgery has left no tumour detectable on examination, endoscopy and pelvic MRI in a high proportion of patients, and surgery and radiation have been deferred rather than performed on schedule. It is not offered as a certainty. A complete response has to be demonstrated first, and close surveillance then continues for years. For MSS or pMMR rectal cancer, which is the large majority, chemoradiation and surgery remain the evidence-based path.
Who is eligible for immunotherapy before rectal cancer surgery?
Five things have to line up. The tumour must be confirmed dMMR or MSI-High on tissue, usually by immunohistochemistry for MLH1, MSH2, MSH6 and PMS2, or by PCR or next-generation sequencing for microsatellite instability. The disease must be rectal, locally advanced, and not spread elsewhere. You must be fit for immunotherapy, without active autoimmune disease needing immune suppression, a transplanted organ, or high baseline steroid doses. You must be able to attend intensive surveillance for years. And a tumour board including a colorectal surgeon must agree, because deferring an operation is a surgical decision as much as a medical one.
What is the evidence for immunotherapy instead of surgery in rectal cancer?
It comes from small cohorts, not from large randomised trials. The result that drew attention was reported from a single centre in the United States in the New England Journal of Medicine in 2022, in a first cohort of about a dozen patients with dMMR locally advanced rectal cancer. All of them had a clinical complete response and did not proceed to surgery or radiation at that point. Larger cohorts and longer follow-up have been reported since. NCCN guidance current as of August 2026 lists checkpoint inhibitor immunotherapy as an option in this setting. In a cohort that small the finding is striking, but it is not a basis for promising the same outcome to any individual patient, and how durable the benefit is over many years is still being established.
What proportion of rectal cancer patients are MSI-High or dMMR?
Roughly 5 to 10 in every 100 rectal cancers, following ranges published in NCCN and ESMO patient guidance current as of August 2026. That is lower than the figure usually quoted for colorectal cancer as a whole, which is around 15 in 100 across all stages and both colon and rectum. Colon cancers, particularly right-sided and stage 2 tumours, are enriched for dMMR. Rectal tumours are not. Reading a colon cancer eligibility figure and applying it to a rectal tumour is one of the commonest reasons families arrive expecting an option that does not apply to them.
What happens if the tumour comes back after surgery was deferred?
Surgery is performed then, and that possibility is planned for from the beginning. This is why the surveillance schedule is intensive rather than routine: repeated digital examination, endoscopy and pelvic MRI at close intervals for years, so that any regrowth is found while an operation is still straightforward. The colorectal surgeon stays involved throughout for exactly this reason. Deferring an operation is not the same as cancelling it. Anyone who takes this pathway is accepting a long follow-up commitment in exchange for the chance of keeping the rectum, and that trade has to be understood before treatment starts, not afterwards.
Why are hepatitis B and C tests done before immunotherapy?
Because a past infection can wake up when the immune system is altered, and screening everyone in advance is routine protocol rather than a judgement about you. Immune-related side effects from checkpoint inhibitor immunotherapy are sometimes managed with steroids or other immune-suppressing medicines, and hepatitis B in particular can reactivate under that suppression. Knowing the status first lets the team arrange monitoring, or preventive antiviral cover, before treatment starts. Thyroid, liver, kidney and blood-count baselines are recorded at the same visit, so that any later change can be identified as an immune-related effect instead of guessed at.
This page is general patient-education information, not a substitute for the written guidance an oncology team gives based on your own pathology report, MMR/MSI result, pelvic MRI and treatment plan.